US equities
|
SPCX
$159.31
▲+7.79%
META
$697.52
▲+0.47%
NVDA
$221.97
▲+2.54%
MU
$913.67
▲+1.96%
TSLA
$386.47
▲+3.41%
AAPL
$343.99
▲+1.32%
AMD
$552.72
▲+3.36%
GOOGL
$334.76
▼-1.62%
SPCX
$159.31
▲+7.79%
META
$697.52
▲+0.47%
NVDA
$221.97
▲+2.54%
MU
$913.67
▲+1.96%
TSLA
$386.47
▲+3.41%
AAPL
$343.99
▲+1.32%
AMD
$552.72
▲+3.36%
GOOGL
$334.76
▼-1.62%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
CareDx, Inc. - Common Stock
(NQ:
CDNA
)
70.74
+1.54 (+2.23%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about CareDx, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
CareDx (NASDAQ:CDNA) Stands Out for High Growth and Improving Fundamentals
↗
October 12, 2026
Via
Chartmill
CAREDX INC (NASDAQ:CDNA): High Growth and Improving Fundamentals Fuel Bullish Case
↗
September 19, 2026
Via
Chartmill
CareDx (NASDAQ:CDNA) Meets Minervini Trend Template with High-Growth Momentum
↗
September 10, 2026
Via
Chartmill
CareDx (NASDAQ:CDNA) Screens Well on High Growth Momentum and Breakout Setup
↗
September 05, 2026
Via
Chartmill
CareDx (NASDAQ:CDNA) Shows Strong Growth Fundamentals by Passing All Eight Rules of Navellier's Screen
↗
August 28, 2026
Via
Chartmill
CareDx (NASDAQ:CDNA) Combines Strong Growth With a Bullish Technical Setup
↗
August 25, 2026
Via
Chartmill
CareDx (NASDAQ:CDNA) Passes Minervini Trend Template and High Growth Momentum Screen
↗
August 19, 2026
Via
Chartmill
CareDx (NASDAQ:CDNA) Posts Accelerating Growth and Strengthening Fundamentals
↗
August 06, 2026
Via
Chartmill
Why CareDx Stock Jumped Today
↗
July 31, 2026
The diagnostics leader is accelerating the trend toward precision medicine.
Via
The Motley Fool
CareDx (NASDAQ:CDNA) Passes Both the Minervini Trend Template and High Growth Momentum Tests
↗
June 20, 2026
Via
Chartmill
CAREDX INC (NASDAQ:CDNA) Shows Perfect Minervini Trend Template and High Growth Momentum Setup
↗
May 30, 2026
Via
Chartmill
CareDx (NASDAQ:CDNA) Beats Q1 Estimates and Raises Full-Year Guidance, But Stock Slips
↗
April 28, 2026
Via
Chartmill
CareDx Inc (NASDAQ:CDNA) Reports Strong Revenue Beat but Profitability Concerns Weigh on Shares
↗
February 24, 2026
Via
Chartmill
CareDx Q2 Earnings Call Highlights
↗
July 30, 2026
CareDx (NASDAQ:CDNA) reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began...
Via
MarketBeat
Topics
Earnings
What's going on in today's session
↗
July 16, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
July 16, 2026
Via
Chartmill
CareDx's CEO Sells 17K Shares
↗
June 21, 2026
CareDx, a leader in transplant diagnostics, saw a key insider reduce his direct holdings amid a series of scheduled transactions.
Via
The Motley Fool
Topics
Regulatory Compliance
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
↗
June 08, 2026
CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted...
Via
MarketBeat
Topics
Intellectual Property
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
↗
June 07, 2026
CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing...
Via
MarketBeat
CareDx (CDNA) Q1 2026 Earnings Call Transcript
↗
April 28, 2026
CareDx (CDNA) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Get insights into the top gainers and losers of Tuesday's after-hours session.
↗
April 28, 2026
Via
Chartmill
CareDx (CDNA) Q2 2025 Earnings Transcript
↗
April 28, 2026
CareDx (CDNA) Q2 2025 Earnings Transcript
Via
The Motley Fool
Thursday's session: gap up and gap down stocks
↗
April 16, 2026
Via
Chartmill
CareDx (CDNA) Q4 2025 Earnings Call Transcript
↗
February 24, 2026
CareDx (CDNA) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Power Solutions Stock Up 140% as $6.36 Million Exit Follows 62% Sales Surge
↗
February 16, 2026
Power Solutions International designs and manufactures advanced engines and power systems for industrial and transportation markets.
Via
The Motley Fool
Topics
Energy
Regulatory Compliance
Freshworks Falls 60% in a Year as $7.5 Million Sale Shrinks Stake to 3.1% of This Portfolio's Assets
↗
February 16, 2026
This SaaS firm delivers cloud-based business software worldwide, focusing on subscription-driven customer and IT service solutions.
Via
The Motley Fool
Topics
Regulatory Compliance
Air Lease Stock Up 43% as Investor Trims $6.9 Million Stake Despite $1 Billion Profit Year
↗
February 16, 2026
Air Lease Corporation provides global airlines with commercial jet leasing, sales, and fleet management services across a diverse portfolio.
Via
The Motley Fool
Topics
Regulatory Compliance
Five9 Stock Down 60% This Past Year, but One Investor Just Lifted Stake With $3.5 Million Buy
↗
February 16, 2026
Five9 delivers cloud-based contact center software for enterprises, serving clients across finance, healthcare, and technology sectors.
Via
The Motley Fool
Freshworks Stock Down 60% in One Year as Revenue Jumps 16% and One Investor Sells $7 Million in Shares
↗
February 16, 2026
Freshworks delivers cloud-based SaaS solutions for customer engagement, IT service management, and business process automation.
Via
The Motley Fool
Topics
Regulatory Compliance
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026
↗
February 01, 2026
The CEO of this leading medical diagnostic company sold shares throughout multiple days in January. But the manner in which the shares were sold shouldn't concern investors.
Via
The Motley Fool
Topics
Regulatory Compliance
< Previous
1
2
3
4
5
6
Next >
